Retatrutide vs Tirzepatide
Side-by-side comparison of Retatrutide, Tirzepatide — mechanism, dosing, half-life, side effects, and research status.
| Attribute | Retatrutide Retatrutide (GIP/GLP-1/Glucagon Triple Agonist) Weight Loss | Tirzepatide Tirzepatide (GIP/GLP-1 Dual Agonist) Weight Loss |
|---|---|---|
| Basics | ||
| Molecular type | Triple GIP/GLP-1/Glucagon Receptor Agonist | Dual GIP/GLP-1 Receptor Agonist |
| Amino acids | — | 39 |
| Molecular weight | — | 4,813.5 Da |
| Half-life | ~6 days | ~5 days |
| Route(s) | Subcutaneous injection | Subcutaneous injection |
| Mechanism & Research | ||
| Primary mechanism | Retatrutide activates three incretin and metabolic hormone receptors simultaneously. GLP-1 receptor agonism drives appetite suppression, slows gastric emptying, and reduces food intake — the primary mechanism shared with… | Tirzepatide's dual mechanism differentiates it from pure GLP-1 agonists. The GIP component contributes additional appetite suppression via hypothalamic GIP receptors and improves insulin secretion efficiency. The two inc… |
| Research status | Phase 3 Trial | FDA Approved |
| Evidence summary | Retatrutide is in Phase 3 clinical trials (NCT06052826) as of 2026, following highly positive Phase 2 data. The Phase 2 trial (NCT04881760, n=338) is the strongest weight loss signal from any pharmacological agent in hum… | Tirzepatide's clinical development programme (SURPASS for diabetes, SURMOUNT for obesity) has consistently demonstrated superior weight loss outcomes to comparator GLP-1 agonists. The SURMOUNT-1 trial set a new benchmark… |
| Protocol & Dosing | ||
| Typical dose | 2mg → 12mg weekly (titration) | 2.5mg → 15mg weekly |
| Frequency | Once weekly | Once weekly |
| Duration | Ongoing (Phase 3) | Ongoing (chronic) |
| Timing | Same day each week | Same day each week, any time of day |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Not Prohibited |
| Deeper reading | ||
| Related peptides | Tirzepatide, Semaglutide, AOD-9604 | Semaglutide, AOD-9604, Tesamorelin |
| Full profile | Read full Retatrutide profile → | Read full Tirzepatide profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.